Bavarian Nordic Smallpox Vaccine Is Imvamune; U.S. Trials To Commence This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to begin large-scale production by mid-2005 and plans to seek a U.S. commercialization partner for the third-generation smallpox vaccine.